SUSPECT ADVERSE REACTION REPORT

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last)	1a. COUNTRY	2. DATE OF BIRTH			2a. AGE	3. SEX	3a. WEIGHT	4-6 REACTION ONSET		
		Day	Month	Year				Day	Month	Year
UNKNOWN	CHINA	26	JUN	2025	1 Months	Female	3.42 kg	04	JUL	2025

7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data)
Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas)

Other Serious Criteria: Medically Significant, IMPORTANT MEDICAL EVENT
PLATELETS DECREASED [Platelet count decreased]

Case Description: Case reference number 2025CHF05807 is a report sent by other health professional and received through regulatory authority (regulatory authority number: 330108175085920250012 6) via Chinese affiliate (local country number: CC202508017) which refers to a female patient aged 1 month (Han nationality).

(Continued on Additional Information Page)

8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION

- ☐ PATIENT DIED
- ☐ INVOLVED OR PROLONGED INPATIENT HOSPITALISATION
- ☐ INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY
- ☐ LIFE THREATENING
- ☐ CONGENITAL ANOMALY
- ☒ OTHER: IMPORTANT

II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name)
#1) PEYONA (CAFFEINE CITRATE) Solution for infusion and oral solution, 20 milligram per millilitre {Lot # 25815}
(Continued on Additional Information Page)

15. DAILY DOSE(S)
#1) 12 milligram, QD

16. ROUTE(S) OF ADMINISTRATION
#1) Intravenous use

17. INDICATION(S) FOR USE
#1) APNOEA (Infantile apnoea)
(Continued on Additional Information Page)

18. THERAPY DATES(from/to)
#1) 01-JUL-2025 / 05-JUL-2025

19. THERAPY DURATION
#1) 4 days

20. DID REACTION ABATE AFTER STOPPING DRUG?
☒ YES ☐ NO ☐ NA

21. DID REACTION REAPPEAR AFTER REINTRODUCTION?
☐ YES ☐ NO ☒ NA

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)
#1) Sodium chloride (Sodium chloride) Injection ; 01-JUL-2025 / 05-JUL-2025

23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)

From/To Dates	Type of History / Notes	Description
Unknown		

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER
Chiesi Farmaceutici SpA
via Palermo, 26/A
Parma, 43122 ITALY

26. REMARKS
Medically Confirmed: Yes
World Wide #: CN-CHIESI-2025CHF05807

24b. MFR CONTROL NO.
2025CHF05807

24c. DATE RECEIVED BY MANUFACTURER
22-AUG-2025

24d. REPORT SOURCE
☐ STUDY ☐ LITERATURE
☒ HEALTH PROFESSIONAL ☒ OTHER: Regulatory Authority

DATE OF THIS REPORT
29-AUG-2025

25a. REPORT TYPE
☐ INITIAL ☒ FOLLOWUP: 1

25b. NAME AND ADDRESS OF REPORTER

CHINA

Mfr. Control Number: 2025CHF05807

ADDITIONAL INFORMATION

7+13. DESCRIBE REACTION(S) continued

Past medical/drug history have not been provided. The patient previous adverse drug reaction and family adverse drug reaction history were unknown.

On 01-Jul-2025 before medication, the patient's platelet count was at 204 billion per liter.

On 01-Jul-2025, the patient was administered Peyona [caffeine citrate] (solution for infusion and oral solution, 20mg/ml, intravenous, batch/lot no: 25815) at 12 mg daily for apnoea neonatal.

The patient was also under treatment with sodium chloride (injection) at 3 ml for solvent (medication dilution) (01-Jul-2025 to 05-Jul-2025).

On 04-Jul-2025, the patient experienced a significant medical event of platelet decreased. Relevant drugs were investigated and considered to be an adverse reaction of caffeine citrate injection.

On 04-Jul-2025, the patient's platelet count was at 27 billion per liter.

Suspected drug was withdrawn on 05-Jul-2025. After discontinuation, the platelet counts gradually increased.

On 09-Jul-2025, the platelet count was at 153 billion per liter, and on the same day the patient recovered from the event.

The reporter considered the event as possible related to Peyona.

No further information is expected as the case was received from regulatory authority.

Update no.01 (22-Aug-2025)

This is a significant follow-up.

Follow-up received from the regulatory authority (regulatory reference number: 330102110115062025000082).

Additional indication of purulent meningitis for suspect drug Peyona was added.

No further information is expected as the case was received from regulatory authority.

Case comments:
This 1 month-old female neonate experienced platelets decreased while being treated with Peyona [caffeine citrate] (solution for infusion and oral solution, 20 mg/ml, intravenous use, batch/lot no: 25815) at 12 mg daily for apnoea neonatal and purulent meningitis.
The event platelets decreased was assessed as serious (seriousness criterion: medically significant).
The platelets decreased is not a listed adverse reaction for Peyona according to the reference safety information.
The adverse reaction of platelets decreased is unexpected as per Canadian Product Monograph.
It was reported that, on 04-Jul-2025, the patient's platelet count was at 27 × 109/L. Relevant drugs were investigated and considered to be an adverse reaction of Caffeine Citrate injection. Caffeine Citrate injection was immediately stopped on 05-Jul-2025. After discontinuation, the platelet count gradually increased.
With respect to platelets decreased, underlying condition of purulent meningitis could provide an alternative explanation, however, considering the drug to event temporal relationship and recovery of event after withdrawal of suspect drug, the causal role of suspect drug seems likely.
The company has assessed causal relationship between Peyona and platelets decreased as probably related in accordance with the WHO-UMC causality assessment method.
The single individual case report does not modify the benefit / risk balance of this product. Therefore, no changes in the label or other measures are recommended at this point. However, the company will continue to monitor all respective reports received and based on cumulative experience, will re-evaluate the available evidence on an ongoing basis.

13. Lab Data

#	Date	Test / Assessment / Notes	Results	Normal High / Low
1	01-JUL-2025	Platelet count	204 billion per litre	
2	04-JUL-2025	Platelet count	27 billion per litre	
3	09-JUL-2025	Platelet count	153 billion per litre	

14-19. SUSPECT DRUG(S) continued

14. SUSPECT DRUG(S) (include generic name)	15. DAILY DOSE(S); 16. ROUTE(S) OF ADMIN	17. INDICATION(S) FOR USE	18. THERAPY DATES (from/to); 19. THERAPY DURATION

Mfr. Control Number: 2025CHF05807

ADDITIONAL INFORMATION

14-19. SUSPECT DRUG(S) continued

14. SUSPECT DRUG(S) (include generic name)	15. DAILY DOSE(S); 16. ROUTE(S) OF ADMIN	17. INDICATION(S) FOR USE	18. THERAPY DATES (from/to); 19. THERAPY DURATION
#1) PEYONA (CAFFEINE CITRATE) Solution for infusion and oral solution, 20 milligram per millilitre {Lot # 25815}; Regimen #1	12 milligram, QD; Intravenous use	APNOEA (Infantile apnoea) PURULENT MENINGITIS (Meningitis bacterial)	01-JUL-2025 / 05-JUL-2025; 4 days